SCHEMBL4357779

SCHEMBL4357779

Cc1c(Cl)cc(N(S)C(=O)Nc2ccccc2C(F)(F)F)c(O)c1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.43
ALDH1A1 P00352 8/20 0.41
TSHR P16473 1/20 0.41
GRIK1 P39086 1/20 0.40
RORC P51449 1/20 0.40
GAA P10253 1/20 0.39
NR3C1 P04150 1/20 0.38
ALOX12 P18054 4/20 0.38
NPSR1 Q6W5P4 2/20 0.38
MAPT P10636 2/20 0.38
PLA2G1B P04054 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
ATG4B Q9Y4P1 1/20 0.38
HPGD P15428 1/20 0.38
KMT2A Q03164 2/20 0.38
POLB P06746 1/20 0.38
MAPK1 P28482 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4347517 0.83 GRIK1 (0.45) HTTTSHRGRIK1RORCGAA
SCHEMBL6567536 0.81 SMN1; SMN2 (0.39) HTTALDH1A1TSHRGRIK1RORC
SCHEMBL4346890 0.81 KMT2A (0.43) HTTALDH1A1GRIK1RORCGAA
SCHEMBL4349377 0.80 EGFR (0.41) ALDH1A1GAANPSR1MAPTHPGD
SCHEMBL4347869 0.80 MTOR (0.43) HTTRORCMAPTKMT2AMEN1
SCHEMBL4347508 0.79 GRIK1 (0.44) HTTALDH1A1TSHRGRIK1RORC
SCHEMBL4345929 0.79 SMN1; SMN2 (0.44) HTTALDH1A1TSHRGRIK1GAA
SCHEMBL4354228 0.78 GRIK1 (0.40) HTTALDH1A1TSHRGRIK1GAA
SCHEMBL4356224 0.77 GRIK1 (0.51) HTTTSHRGRIK1RORCGAA
SCHEMBL4345871 0.77 GRIK1 (0.51) HTTTSHRGRIK1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
EP-1402887-A1 New compounds for the inhibition of undesired cell proliferation and use thereof Jerini AG (DE) 2004-03-31 EP claimed
EP-1402888-A1 The use of substituted carbocyclic compounds as rotamases inhibitors Jerini AG (DE) 2004-03-31 EP claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 HTT 3824/4885ALDH1A1 2565/4885TSHR 1112/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 HTT 3995/4885ALDH1A1 2767/4885TSHR 1455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.